EVH

Evolent Health Inc

Add to Watchlist

Advanced Chart

9.220

+0.22(2.444%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

9.8116

Open

9.180

VWAP

9.30

Vol

2.45M

Mkt Cap

1.07B

Low

8.910

Amount

22.73M

EV/EBITDA(TTM)

15.73

Total Shares

114.68M

1.94B

EV/OCF(TTM)

P/S(TTM)

0.47

Evolent Health, Inc. is a health care company connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. The Company offers three primary solutions: specialty care management services, total cost of care management and administrative services. It provides comprehensive quality management for oncology and cardiology patients from diagnosis through advanced care planning services, as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its total cost of care management solution enables providers to manage populations they may be accountable for under value-based contracts with payers or accountable care organizations (ACO) contracts with Centers for Medicare and Medicaid Services (CMS). Its administrative services solution includes an integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

574.29M

+18.74%

0.130

+116.02%

515.30M

-20.3%

0.130

-750.9%

500.91M

-19.39%

0.114

+184.75%

Estimates Revision

The market is revising Downward the revenue expectations for Evolent Health, Inc. (EVH) for FY2025, with the revenue forecasts being adjusted by -0.24% over the past three months. During the same period, the stock price has changed by -0.97%.

Revenue Estimates for FY2025

Revise Downward

-0.24%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-12.43%

In Past 3 Month

Stock Price

Go Down

-0.97%

In Past 3 Month

11 Analyst Rating

56.62% Upside

Wall Street analysts forecast EVH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVH is 14.44 USD with a low forecast of 10.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

1 Hold

0 Sell

Strong Buy

56.62% Upside

Current: 9.220

Low

10.00

Averages

14.44

High

20.00

56.62% Upside

Current: 9.220

Low

10.00

Averages

14.44

High

20.00

Truist

Jailendra Singh

Buy

maintain

$14 -> $16

2025-07-17

Reason

Truist

Jailendra Singh

Price Target

$14 -> $16

2025-07-17

maintain

Buy

Reason

Truist analyst Jailendra Singh raised the firm's price target on Evolent Health to $16 from $14 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 results for Health Care IT / Digital Health sector names. Despite the strong YTD outperformance in shares, investor sentiment still remains relatively mixed, with the interest level from long-onlies/generalist investors seen as "relatively selective", the analyst tells investors in a research note. HCIT space has also benefited from the lack of direct tariff exposure and other macro uncertainty as well as renewed capital market activity, the firm added.

UBS

Kevin Caliendo

Buy

maintain

$14 -> $15

2025-05-09

Reason

UBS

Kevin Caliendo

Price Target

$14 -> $15

2025-05-09

maintain

Buy

Reason

UBS analyst Kevin Caliendo raised the firm's price target on Evolent Health to $15 from $14 and keeps a Buy rating on the shares. Evolent Health has better visibility into its future financials and growth algorithm than it did just five months ago following the repricing and recontracting of its major customer contracts, the analyst tells investors in a research note. The first quarter was a first step toward regaining credibility with shareholders and UBS sees the risk-reward as positive.

Truist Securities

Jailendra Singh

Strong Buy

Maintains

$15 → $14

2025-04-10

Reason

Truist Securities

Jailendra Singh

Price Target

$15 → $14

2025-04-10

Maintains

Strong Buy

Reason

Truist analyst Jailendra Singh lowered the firm's price target on Evolent Health to $14 from $15 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results in the Healthcare IT industry. The industry is typically shielded from macro uncertainty, but tariffs and concerns around an economic slowdown have created broader market uncertainty, which is never good for a high-beta highly volatile group like HCIT/Digital Health/Payviders, the analyst tells investors in a research note. Truist adds that while HCIT companies may not be directly exposed to new tariffs, several of these companies serve end markets - hospitals, pharma, etc. - which are likely to see either some direct impact on their supply chain costs or could decide to slow down on their investments.

JP Morgan

Anne Samuel

Buy

Maintains

$13 → $12

2025-03-10

Reason

JP Morgan

Anne Samuel

Price Target

$13 → $12

2025-03-10

Maintains

Buy

Reason

JPMorgan lowered the firm's price target on Evolent Health to $12 from $13 and keeps an Overweight rating on the shares. Evolent Health has acquired three businesses since 2020 that have significantly increased its runway for growth, with much remaining as healthcare transitions to a new payment mode, the analyst tells investors in a research note. The firm believes P&L accountability of the execution of the strategy will be demonstrated in the forward results.

Citizens Capital Markets

Constantine Davides

Buy

Maintains

$13 → $12

2025-02-24

Reason

Citizens Capital Markets

Constantine Davides

Price Target

$13 → $12

2025-02-24

Maintains

Buy

Reason

Citizens JMP raised the firm's price target on Evolent Health to $13 from $12 and keeps an Outperform rating on the shares. Evolent's Q4 revenue trailed consensus, while adjusted EBITDA was also below consensus, largely the result of elevated oncology costs, the analyst tells investors in a research note. While 2024 was a challenging year for Evolent, the firm believes management has taken the appropriate steps to insulate its business from factors outside its control, and profit generation should prove more predictable and durable than it was entering 2024.

Piper Sandler

Jessica Tassan

Buy

Reiterates

$17 → $16

2025-02-21

Reason

Piper Sandler

Jessica Tassan

Price Target

$17 → $16

2025-02-21

Reiterates

Buy

Reason

Piper Sandler lowered the firm's price target on Evolent Health to $16 from $17 and keeps an Overweight rating on the shares. The firm says the company reported Q4 results at the low end of revenue and adjusted EBITDA guidance, but better than feared in its view. Piper likes the 2025 outlook implying $150M of adjusted EBITDA at the midpoint, which it believes is appropriately calibrated given the oncology cost trend acceleration observed in Q4.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Evolent Health Inc (EVH.N) is 16.91, compared to its 5-year average forward P/E of 22.07. For a more detailed relative valuation and DCF analysis to assess Evolent Health Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

22.07

Current PE

16.91

Overvalued PE

289.52

Undervalued PE

-245.38

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

22.66

Current EV/EBITDA

11.84

Overvalued EV/EBITDA

31.54

Undervalued EV/EBITDA

13.79

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

1.49

Current PS

0.48

Overvalued PS

2.06

Undervalued PS

0.91